Target intelligence / Profile preview

Elongin C pseudogene 29 (ELOCP29)

Target: ELOCP29
Molecular classification: Other (pseudogene)

Overview

Elongin C pseudogene 29 (ELOCP29) is a *pseudogene* located in the human genome, with the alias TCEB1P29. As a pseudogene, it is a nonfunctional copy of the gene encoding elongin C, which itself is a regulatory subunit of the transcription factor B (SIII) complex involved in RNA polymerase II-mediated transcriptional elongation[1][4]. ELOCP29 does not encode a functional protein, lacks known biological function, and has no recognized role as a therapeutic target or disease-associated gene. Pseudogenes are typically classified as genetic relics that may sometimes exert regulatory effects via RNA, but no evidence supports such function for ELOCP29 at present[2][4]. There are no known drugs, mechanisms, biomarkers, or therapeutic indications associated with this locus.

Other names: TCEB1P29

Beyond the preview

Go deeper on Elongin C pseudogene 29 (ELOCP29).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elongin C pseudogene 29 (ELOCP29).

Explore the full profile